Compare MLYS & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLYS | INSP |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2023 | 2018 |
| Metric | MLYS | INSP |
|---|---|---|
| Price | $32.32 | $92.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 16 |
| Target Price | $47.33 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 02-11-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.77 |
| EPS | N/A | ★ 1.48 |
| Revenue | N/A | ★ $882,622,000.00 |
| Revenue This Year | N/A | $15.15 |
| Revenue Next Year | N/A | $10.98 |
| P/E Ratio | ★ N/A | $62.48 |
| Revenue Growth | N/A | ★ 16.81 |
| 52 Week Low | $8.24 | $70.77 |
| 52 Week High | $47.65 | $203.12 |
| Indicator | MLYS | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 33.20 | 41.03 |
| Support Level | $31.67 | $91.11 |
| Resistance Level | $33.64 | $97.72 |
| Average True Range (ATR) | 1.67 | 4.50 |
| MACD | -0.23 | -0.06 |
| Stochastic Oscillator | 19.56 | 16.91 |
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.